Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 6/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.50 |
| ▸ | GRM2 | Q14416 | 2/20 | 0.50 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | GRM8 | O00222 | 2/20 | 0.50 |
| ▸ | GRM6 | O15303 | 2/20 | 0.50 |
| ▸ | ARG1 | P05089 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | GRM5 | P41594 | 1/20 | 0.50 |
| ▸ | MTOR | P42345 | 1/20 | 0.50 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.50 |
| ▸ | PLCB1 | Q9NQ66 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26923301 | 1.00 | GRM4 (0.50) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL2904567 | 1.00 | GRM4 (0.50) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| Hydrochloric Acid SCHEMBL26923446 | 0.98 | ARG1 (0.49) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| Hydrochloric Acid SCHEMBL25393736 | 0.98 | ARG1 (0.49) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| Hydrochloric Acid SCHEMBL26925051 | 0.98 | ARG1 (0.49) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL31415483 | 0.94 | GRM4 (0.48) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL31415421 | 0.94 | GRM4 (0.48) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL2898361 | 0.88 | GRM4 (0.59) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL31415320 | 0.84 | GRM4 (0.46) | GRM4CYP1A2CYP2C19GRM2GRM3 | |
| SCHEMBL31415502 | 0.84 | GRM4 (0.46) | GRM4CYP1A2CYP2C19GRM2GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743085-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-4695231-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | Tenvie Therapeutics Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS INC (US) | 2025-11-27 | — | — | US | disclosed |
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | TENVIE THERAPEUTICS, INC. | 2025-05-29 | — | — | US | disclosed |
| EP-4536637-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-04-16 | — | — | EP | disclosed |
| WO-2025054368-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025054369-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025054366-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-03-13 | — | — | WO | disclosed |
| WO-2025019357-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2025-01-23 | — | — | WO | disclosed |
| EP-4486722-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Nico Therapeutics, Inc. (US) | 2025-01-08 | — | — | EP | disclosed |
| WO-2024216209-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | NICO THERAPEUTICS, INC. (US) | 2024-10-17 | — | — | WO | disclosed |
| WO-2023240084-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023240084-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-12-14 | — | — | WO | disclosed |
| WO-2023168298-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | DENALI THERAPEUTICS INC. (US) | 2023-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171462-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | GRM4 3366/4885CYP1A2 4420/4885CYP2C19 4693/4885 |
| US-20250361234-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS | SARM1, SARS1, TIAM1 | GRM4 2931/4885CYP1A2 4519/4885CYP2C19 4717/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.